Illumina, Inc. $ILMN Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 9.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,896 shares of the life sciences company’s stock after selling 13,742 shares during the period. New York State Teachers Retirement System’s holdings in Illumina were worth $16,751,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. Empowered Funds LLC lifted its position in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in Illumina during the 2nd quarter worth about $621,000. CW Advisors LLC acquired a new stake in Illumina during the 2nd quarter worth about $275,000. Marshall Wace LLP raised its stake in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after buying an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC lifted its holdings in shares of Illumina by 30.9% in the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after buying an additional 1,748 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In other news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total value of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This trade represents a 7.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is owned by insiders.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $188.68 on Friday. The firm has a market cap of $28.55 billion, a price-to-earnings ratio of 34.31, a price-to-earnings-growth ratio of 3.53 and a beta of 1.47. The company’s 50-day simple moving average is $154.74 and its 200-day simple moving average is $139.42. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $189.46.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company posted $0.97 EPS. Illumina’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts predict that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ILMN. Guggenheim lifted their price target on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Barclays lifted their target price on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a report on Wednesday, June 24th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Sanford C. Bernstein started coverage on shares of Illumina in a research report on Friday, June 26th. They issued a “market perform” rating and a $185.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $148.94.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.